Advertisement

Tumor Biology

, Volume 35, Issue 12, pp 11837–11843 | Cite as

Impact of neoadjuvant chemotherapy on lymphocytes and co-inhibitory B7-H4 molecule in gastric cancer: low B7-H4 expression associates with favorable prognosis

  • Ninu Maskey
  • Kai Li
  • Min Hu
  • Zhigao Xu
  • Chunwei Peng
  • Fang Yu
  • Hong Cao
  • Jiamei Chen
  • Yan Li
  • Guifang Yang
Research Article

Abstract

Little is known on the immune response after neoadjuvant chemotherapy (NACT) in gastric cancer (GC). The present study aimed to investigate the effects of NACT on tumor cells and tumor-infiltrating lymphocytes (TILs) in patients with GC. Expressions of CD4+ and CD8+ TILs and identified co-inhibitory B7-H4 molecule were examined by immunohistochemical staining in GC tissues of 56 patients who received NACT (NACT group) and 46 patients who did not receive NACT (nNACT group). These markers, clinicopathological features, and overall survival (OS) time between both groups were compared. Results showed that the clinicopathological features of patients were not significantly associated with NACT (P > 0.05), but the rate of low expression of B7-H4 (78.6 vs. 47.8 %, P = 0.005) and rate of high expression of CD4+ TILs (58.9 vs. 39.1 %, P = 0.048) and CD8+ TILs (92.9 vs. 56.5 %, P < 0.001) were both significantly higher in NACT group than that in nNACT group. Further, Kaplan–Meier analysis indicated that there was no significant difference in OS time between the groups. However, in NACT group, those with low B7-H4 expression had significantly longer OS (P = 0.031). The study findings suggest that low expression of B7-H4 could serve as a candidate biomarker for predicting response to NACT and could provide favorable prognostic information in GC.

Keywords

Gastric cancer Neoadjuvant chemotherapy B7-H4 Tumor-infiltrating lymphocytes CD4 CD8 

Notes

Acknowledgments

This research was supported by the grants from the Natural Science Foundation of Hubei Province, China (No. 2013CFB267) and Wuhan Science and Technology Key Project (No. 2013060602010248).

Conflicts of interest

None

References

  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRefGoogle Scholar
  2. 2.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–50.PubMedCrossRefGoogle Scholar
  3. 3.
    Zou XN, Duan JJ, Huangfu XM, Chen WQ, Zhao P. Analysis of stomach cancer mortality in the national retrospective sampling survey of death causes in China, 2004–2005. Zhonghua Yu Fang Yi Xue Za Zhi. 2010;44(5):390–7.PubMedGoogle Scholar
  4. 4.
    Lin Y, Ueda J, Kikuchi S, Totsuka Y, Wei WQ, Qiao YL, et al. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol. 2011;17(39):4421–8.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Schuhmacher C, Reim D, Novotny A. Neoadjuvant treatment for gastric cancer. J Gastric Cancer. 2013;13(2):73–8.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Dikken JL, van de Velde CJ, Coit DG, Shah MA, Verheji M, Cats A. Treatment of resectable gastric cancer. Ther Adv Gastroenterol. 2012;5(1):49–69.CrossRefGoogle Scholar
  7. 7.
    Bozzetti F, Gianotti L, Braga M, Di Carlo V, Mariani L. Postoperative complications in gastrointestinal cancer patients: the joint role of the nutritional status and the nutritional support. Clin Nutr. 2007;26(6):698–709.PubMedCrossRefGoogle Scholar
  8. 8.
    Mezhir JJ, Tang LH, Coit DG. Neoadjuvant therapy of locally advanced gastric cancer. J Surg Oncol. 2010;101(4):305–14.PubMedCrossRefGoogle Scholar
  9. 9.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Li ZY, Koh CE, Bu ZD, Wu AW, Zhang LH, Wu XJ, et al. Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer. J Surg Oncol. 2012;105(8):793–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Lorenzen S, Blank S, Lordick F, Siewert JR, Ott K. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Ann Surg Oncol. 2012;19(7):2119–27.PubMedCrossRefGoogle Scholar
  12. 12.
    Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011;7(5):651–8.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003;18(6):849–61.PubMedCrossRefGoogle Scholar
  14. 14.
    Mugler KC, Singh M, Tringler B, Torkko KC, Liu W, Papkoff J, et al. B7-H4 expression in a range of breast pathology: correlation with tumor T-cell infiltration. Appl Immunohistochem Mol Morphol. 2007;15(4):363–70.PubMedCrossRefGoogle Scholar
  15. 15.
    Chen LJ, Sun J, Wu HY, Zhou SM, Tan Y, Tan M, et al. B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother. 2011;60(7):1047–55.PubMedCrossRefGoogle Scholar
  16. 16.
    Liang M, Li JY, Wang DD, Li SC, Sun Y, Sun TW, et al. T-cell infiltration and expressions of T lymphocyte co-inhibitory B7-H1 and B7-H4 molecules among colorectal cancer patients in northeast China’s Heilongjiang Province. Tumor Biol. 2014;35(1):55–60.CrossRefGoogle Scholar
  17. 17.
    Zhang L, Wu H, Lu D, Li G, Sun C, Song H, et al. The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene. 2013;32(46):5347–58.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Arigami T, Uenosono Y, Ishigami S, Hagihara T, Haraguchi N, Natsugoe S. Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer. World J Surg. 2011;35(9):2051–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Jiang JT, Zhu YB, Wu CP, Shen YP, Wei WX, Chen L, et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother. 2010;59(11):1707–14.PubMedCrossRefGoogle Scholar
  20. 20.
    Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rebe C, et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol. 2011;224(3):389–400.PubMedCrossRefGoogle Scholar
  21. 21.
    Tsuchikawa T, Md MM, Yamamura Y, Shichinohe T, Hirano S, Kondo S. The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;19(5):1713–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMedGoogle Scholar
  23. 23.
    Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17(12):3077–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol Med. 2008;14(12):550–9.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Shurin MR. Dual role of immunomodulation by anticancer chemotherapy. Nat Med. 2013;19(1):20–2.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012;11(3):215–33.PubMedCrossRefGoogle Scholar
  27. 27.
    Rahir G, Moser M. Tumor microenvironment and lymphocyte infiltration. Cancer Immunol Immunother. 2012;61(6):751–9.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Ninu Maskey
    • 1
  • Kai Li
    • 1
  • Min Hu
    • 1
  • Zhigao Xu
    • 1
  • Chunwei Peng
    • 2
  • Fang Yu
    • 1
  • Hong Cao
    • 1
  • Jiamei Chen
    • 2
  • Yan Li
    • 2
  • Guifang Yang
    • 1
  1. 1.Department of Pathology, Zhongnan HospitalWuhan UniversityWuhanPeople’s Republic of China
  2. 2.Department of Oncology, Zhongnan Hospital, Hubei Key Laboratory of Tumor Biological BehaviorsWuhan UniversityWuhanPeople’s Republic of China

Personalised recommendations